Long Island Hotels Now Offer Revolutionary Nicotine Tablet Nicofi™ for a Smoke-Less Overnight StayJust-Unveiled Tablet Allows Guests to Enjoy Nicotine in Non-Smoking Hotels and Public Places
WESTBURY, NY – JULY 6, 2015 – Three Long Island hotels are charting new territory offering a new smoke-less nicotine alternative to its guests called Nicofi™. The just-unveiled product is available at the Sheraton Four Points Plainview, The Inn at Great Neck and Viana Hotel & Spa. Nicofi is a nicotine alternative to smoking for guests who are unable to have a cigarette or e-cigarette in their hotel room or other public places.
Nicofi is a small sublingual tablet made from pure nicotine and other high-quality ingredients that dissolves under the tongue (no chewing or swallowing) and allows smokers to quickly and discreetly enjoy nicotine in any situation.
Made in the U.S.A. by Ross Myles Health (sister company of Long Island-based PL Developments), Nicofi is a revolutionary product for adults who are looking to substitute smoking a cigarette or e-cigarette and has no harmful ingredients (no tar, tobacco or formaldehyde).
“We appreciate that there are more than 42 million Americans who still smoke and find themselves in daily instances, like staying in a hotel room, where they are unable to smoke cigarettes or e-cigarettes,” said Evan Singer, President of Nicofi. “That’s why we launched Nicofi – to answer the smoker’s need for fast-acting, discreet, convenient and pure delivery of nicotine.”
With its IntraTab™ Drug Delivery Technology, Nicofi releases a solution of nicotine directly into the bloodstream through the lining of the mouth. It was studied in controlled trials and clinically proven* to deliver nicotine quickly, similar to smoking a cigarette and is two to three times faster than nicotine gum and lozenges.*
One Nicofi tablet is equivalent to the approximate amount of nicotine received from one cigarette. It is recommended to take one tablet at a time without exceeding 20 tablets per day.
Nicofi is now available at select retailers and on www.nicofi.com.
*Based on open-label, single-dose pharmacokinetic evaluation of NicofiTM 1mg sublingual tablets in healthy smokers under fasted conditions, as demonstrated by similar blood PK parameters (tmax, Cmax, AUC), compared to nicotine polacrilex gum and lozenges as reported in the scientific literature: Pharmacokinetics of Nicotine Polacrilex Gum, Nicotine & Tobacco Research, Volume 5, Number 5 (October 2003) 635-644.